TY - JOUR
T1 - Androgeenreceptorremming tegen prostaatkanker
T2 - nieuwe middelen, maar voor welke patiënt?
AU - Vis, André N
AU - van Moorselaar, R J A
PY - 2019/11/28
Y1 - 2019/11/28
N2 - The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo. The trial included 1509 men with a prostate-specific antigen doubling time of 10 months or less. Non-metastatic disease was defined as the absence of metastases, using conventional imaging rather than the substantially more sensitive PSMA scans. The effect of darolutamide is similar to that of other androgen inhibitors, such as apalutamide and enzalutamide. The value of the current trial to Dutch clinical practice is limited, as the number of patients with non-metastatic, castration-resistant prostate cancer is low due to the increased use of PSMA scans and the reluctance of urologists to start androgen-deprivation therapy in the absence of metastatic disease.
AB - The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo. The trial included 1509 men with a prostate-specific antigen doubling time of 10 months or less. Non-metastatic disease was defined as the absence of metastases, using conventional imaging rather than the substantially more sensitive PSMA scans. The effect of darolutamide is similar to that of other androgen inhibitors, such as apalutamide and enzalutamide. The value of the current trial to Dutch clinical practice is limited, as the number of patients with non-metastatic, castration-resistant prostate cancer is low due to the increased use of PSMA scans and the reluctance of urologists to start androgen-deprivation therapy in the absence of metastatic disease.
KW - Androgen Receptor Antagonists/pharmacology
KW - Antineoplastic Agents/pharmacology
KW - Humans
KW - Male
KW - Neoplasm Staging
KW - Netherlands
KW - Patient Selection
KW - Positron-Emission Tomography
KW - Prostate/diagnostic imaging
KW - Prostatic Neoplasms, Castration-Resistant/drug therapy
KW - Pyrazoles/pharmacology
KW - Randomized Controlled Trials as Topic
M3 - Article
C2 - 32073798
VL - 163
JO - Nederlands Tijdschrift voor Geneeskunde
JF - Nederlands Tijdschrift voor Geneeskunde
SN - 0028-2162
ER -